Regulatory milestone clears path for clinical laboratories to use Illumina NGS technology
This Smart News Release features multimedia. View the full release here:http://www.businesswire.com/news/home/20160509006263/en/
“This is an exciting milestone for the clinical market in South Korea,” said
The MiSeqDx Instrument offers users the ability to perform NGS for diagnostic or research applications on a single, easy-to-use system. Designed and validated for the clinical market, the instrument harnesses Illumina’s industry-leading sequencing by synthesis (SBS) chemistry giving laboratories high confidence in their results.
“Illumina is thrilled to receive this regulatory approval,” added
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160509006263/en/
Source:
Illumina, Inc.
Investors:
Rebecca Chambers, 858-255-5243
ir@illumina.com
or
Media:
Gwen Gordon, 858-882-6822
pr@illumina.com